Welcome to our dedicated page for Global Innovative Platforms SEC filings (Ticker: GIPL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Global Innovative Platforms Inc. (OTC: GIPL) SEC filings page on Stock Titan provides access to the company’s official regulatory documents, including Forms 10‑K, 8‑K, and related notices. These filings describe the company’s focus on breath-based veterinary diagnostics, its VOCAM Plus technology for canine heartworm detection, and key corporate and accounting developments.
Through documents such as Form 12b‑25, investors can see explanations for delays in filing the company’s Annual Report on Form 10‑K and the stated need for additional time to complete compilation and review. Current and historical 8‑K filings detail events like the posting of updated investor presentations, early-stage analysis of breath data using artificial intelligence and multivariate statistical tools, and preliminary findings that breath VOC profiles may distinguish heartworm-positive from negative canine samples.
Other 8‑K filings cover a material definitive agreement with a global animal health company involving the supply of VOCAM Plus units and related support services for evaluation and validation of Global Innovative Platforms’ breathomics-based diagnostic system. Filings also discuss the dismissal of the company’s previous independent registered public accounting firm and the appointment of a new firm, including statements about the absence of disagreements or reportable events under SEC rules.
On Stock Titan, these SEC filings are updated from EDGAR and paired with AI-powered summaries that explain complex sections in plain language. Users can quickly understand the implications of annual reports (Form 10‑K), current reports (Form 8‑K), and notices like Form 12b‑25 without reading every page. This makes it easier to track how Global Innovative Platforms reports on its research progress, corporate agreements, and financial reporting processes over time.
Global Innovative Platforms Inc. posted an updated investor presentation on its website on March 31, 2026. The presentation, which is furnished as Exhibit 99.1, is available under the Investor Relations section of www.vetbreath.com.
The company states that the information in this report and Exhibit 99.1 is furnished under Regulation FD, not filed, and is therefore not subject to certain Exchange Act liabilities or automatically incorporated into other securities law filings.
Global Innovative Platforms Inc. reported its quarterly results for the three months ended December 31, 2025. The animal health diagnostics company generated its first revenue, recording $30,000 from a licensing and evaluation agreement for its Plus breath-analysis technology, but still posted a net loss of $49,429, improved from a $120,467 loss a year earlier. Operating expenses fell as research and development and general and administrative costs declined, helping narrow losses.
Cash and cash equivalents were $49,004 with total assets of $224,951 and current liabilities of $65,784, including $55,500 of deferred revenue tied to its new contract. Accumulated deficit reached $1,304,892, and management again disclosed “substantial doubt” about the company’s ability to continue as a going concern, noting it will need additional debt or equity financing to fund operations and growth. As of February 17, 2026, 47,531,657 common shares were outstanding, reflecting ongoing equity issuance to fund the business.
Global Innovative Platforms Inc. is an early-stage animal health company developing non-invasive breath and air analytics, with an initial focus on a Heartworm Breath Test for dogs using licensed VOCAM Plus gas chromatography devices, FROG units, and Ellvin AI software from Defiant Technologies.
The company remains in research and development, recorded no revenue for the years ended September 30, 2025 and 2024, and reported a retained deficit of approximately $1.25 million, leading its auditors to include a going concern warning. It has billed and collected $85,000 after year-end but still expects to rely on additional debt or equity financing.
Global Innovative Platforms depends heavily on an exclusive license from Defiant for animal and agricultural applications, operates with minimal staff and basic cybersecurity measures, and trades as a thinly traded penny stock on the OTC Expert Market, exposing shareholders to liquidity and volatility risks.
Global Innovative Platforms Inc. filed a notice that its Annual Report on Form 10‑K for the year ended September 30, 2025 will be submitted late. The company states it needs additional time for compilation and review to ensure adequate disclosure of required information in the 10‑K.
Under Rule 12b‑25, the company expects to file the Form 10‑K on or before the 15th calendar day following the prescribed due date, which keeps the filing within the allowed extension window.
Global Innovative Platforms Inc. reported that it has posted an updated investor presentation and shared preliminary scientific results on its VOCAM Plus breath-analysis technology for canine heartworm detection. The company used artificial intelligence and multivariate statistical tools to analyze breath samples from dogs with and without confirmed heartworm and found measurable differences between infected and non‑infected animals.
The study suggests a consistent breath VOC profile associated with heartworm, including in many samples classified as early-stage infection, a phase where current antigen tests cannot yet detect disease for roughly the first six months. In an internal self-prediction test of its model, there was only one misclassification, in which an early heartworm sample was labeled as mature. When the model was applied to the full dataset, trimmed samples did not incorrectly fall into any of the three modeled states. The company plans to continue testing and confirming these early but encouraging findings.
Global Innovative Platforms Inc. (GIPL) filed an 8-K announcing two developments. The company entered into an agreement with a global animal health company to evaluate and validate its proprietary VOCAM Plus breathomics diagnostic technology for detecting heartworm disease in dogs. The company will supply VOCAM Plus units and related support services for this evaluation, with the full agreement to be filed with the next Form 10-K.
The Board changed auditors. On November 3, 2025, it dismissed M. S. Madhava Rao, Chartered Accountant, and appointed CNGSN & Associates LLP as the independent registered public accounting firm for the fiscal year ending September 30, 2025. The prior auditor’s reports for fiscal years 2024 and 2023 contained no adverse opinions or disclaimers, and the company reports no disagreements or reportable events. A letter from the former auditor dated November 6, 2025 is filed as Exhibit 16.1.
Global Innovative Platforms (GIPL) insider Andrew N. Brown, who serves as CEO, CFO and Director and is a 10% owner, reported multiple transactions on Form 4. Reported activity includes open-market purchases at $0.0017 per share, such as 250,000 shares on 09/30/2025 and 273,000 shares on 07/03/2025, plus a gift of 50,416 shares on 06/30/2025. Following these transactions, he directly beneficially owned 10,310,554 shares as shown after the 09/30/2025 entry.
Global Innovative Platforms Inc. furnished an updated investor presentation and posted it on its website on September 26, 2025. The presentation, which outlines information for current and potential investors, is available under the Investor Relations section of www.vetbreath.com and is also provided as Exhibit 99.1 to a current report. The materials are being shared for informational purposes and are designated as furnished rather than filed under securities laws.